Skip to main content
ENDO 2026 Main banner

Cardiovascular Endocrinology

SAT-269 - Lipid-Lowering Efficacy of Statins and Its Safety Profile in Type 2 Diabetes Mellitus

Saturday, June 13, 2026
9:30 AM - 4:30 PM CT
Location: ENDOExpo; Poster Floor
Background
Statin therapy is an effective lipid-lowering therapy in patients with diabetes. Differences in the
efficacy of statins exist based on genetic polymorphisms, race, and ethnicity.
Methodology
We included 158 patients of type 2 diabetes mellitus (T2DM) who were statin naïve in this
prospective observational study. Patients were started on statin therapy, either atorvastatin or
rosuvastatin, based on physician preference. Lipid profile and serum resistin levels were
measured at the initial visit and at 12 weeks of follow-up.
Results
The mean age of the study population was 52.4±8.25 years. About 52.9% of participants were
males. Most common forms of dyslipidemia noted were low levels of high-density lipoprotein-
cholesterol (HDL-C) (64.7%), and elevated low-density lipoprotein-cholesterol (LDL-C) levels
(55.6%). Atorvastatin was the most commonly used statin. The median time to statin initiation
following diabetes diagnosis among eligible patients was approximately three years. The median
percentage decrease in total cholesterol, LDL-C, HDL-C, non-HDL-C, and triglycerides were
23.03%, 29.02%, 3.77%, 30.09%, and 8.43%, respectively. The median baseline and 12-week
follow-up serum resistin levels were 561.49 (307.7-1001.98) pg/mL and 522.68 (292.77-
1029.53) pg/mL, respectively. The percentage change in serum resistin on follow-up was not
significantly different between atorvastatin and rosuvastatin groups (-12.2%vs-17.55%,
p=0.478). No serious adverse events were noted.
Conclusion
Statin therapy over 12 weeks leads to a significant reduction in LDL-C and total cholesterol
without affecting serum resistin levels in Indian patients; however, statin initiation was delayed
despite eligibility. The index study is one of the few studies evaluating the effect of statins on
lipid parameters among T2DM patients and the only Indian study on the effect of statins on
serum resistin levels.

*Unless otherwise noted, all abstracts presented at ENDO must not be released to the press or the public until the date and time of presentation. For oral presentations, the abstracts are embargoed until the session begins. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.*